Navigation Links
VitaTech Adds New Capacity for Production and Customer Interface, Attributes Growth to Strategic Customer Partnerships
Date:6/7/2012

TUSTIN, Calif., June 7, 2012 /PRNewswire/ -- VitaTech International, Inc., announced reaffirmation of its FDA pharmaceutical licensing and new investment of over $2 million in enhanced production capabilities for the manufacturing of tablets, powders and two-piece capsules.  A private label manufacturer of vitamins and nutritional supplements for new and established brands worldwide in health and nutrition, VitaTech has been pharmaceutically licensed since 1954.

"Orders are up and we are off to a great start in 2012," commented CEO Thomas T. Tierney. "Our expertise in product innovation and our commitment to staying ahead of customer wants and regulatory needs has produced excellent results," he said. Tierney attributes the company's growth to its strategic partnerships and its culture of dedication to the success of its customers. "We are a trusted partner, making every detail work in a heavily regulated and highly competitive industry," he said.

VitaTech's recent investment in state-of-the-art tablet and capsule fillers enables the company to press an additional 250,000 tablets per hour, bringing capacity to 3.8 billion tablets per year. "We place a premium on rapid turnaround," says Tierney.

With the installation of segregated overhead feed systems and new technology to automatically reject non-conforming tablets and capsules, VitaTech added enhanced speed and quality assurance to its manufacturing.

The company has expanded encapsulation production, with capacity of up to 1.2 billion capsules annually.  Recent investments in quality control and EDI solutions provide speed, improved data accuracy and streamlined interactions with trading partners.

Leading the West Coast in capacity for continuous coating of vitamins and nutraceuticals, VitaTech also provides comprehensive analytical testing services. Heavy metals and microbiological testing are available on-site in the company's quality assurance/quality control
'/>"/>

SOURCE Vita-Tech International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. National Stakeholders Meet To Consider Improvements In Antimicrobial Use In Food Animal Production
2. Glooko Launches the Glooko™ IR Adapter to Give ACCU-CHEK® Blood Glucose Meter Customers Access to the Glooko Logbook Solution
3. SuccessEHS "Forward Together" Customer Conference Begins
4. New Report Outlines Use of Innovative Marketing to Engage Customer Groups that are Key to the Pharmaceutical Industry
5. Okuma America Chooses The Daniel Group To Provide Customer Service Research
6. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
7. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
8. Millennium Surgical Corp. Announces Sales Figures, Growth
9. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
10. Aethlon Medical to Present at Todays Security Research Associates 8th Annual Growth Conference
11. Veeva Systems Announces Dramatic Growth in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  PENTAX Medical, a healthcare industry leader ... leader in ultrasound imaging, recently announced renewed collaborative ... further innovation in the development of Endoscopic Ultrasound ... and PENTAX Medical endoscopic portfolio have formed one ... systems. This agreement will continue to grow their ...
(Date:5/17/2013)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ( ... announced today that the United States Food and Drug ... application(IND) for ORMD-0801, its oral insulin capsule. ... to proceed," stated Nadav Kidron , ... milestone for Oramed and we look forward to continuing ...
(Date:5/16/2013)... ZURICH , May 17, 2013 ... and Research (A*STAR) and Switzerland,s Cytos ... been dosed in a Phase 1 clinical trial with their ... virus-like particle (VLP) technology. In this first Phase 1 clinical ... and its potential to protect against H1N1 influenza infection will ...
Breaking Medicine Technology:PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... with Two Abstracts Accepted for ... November 2008, BRIDGEWATER, N.J., Sept. 4 ... the treatment of,cardiovascular and metabolic disease, today announced ... Company,s board of directors., Peter Garrambone,s career ...
... Group (NYSE: SCR ), a leading manufacturer ... the patented,anti-cancer biotech product Endu (also known as ... Phase IV clinical study., At the request ... clinical study,to further validate the safety and therapeutic ...
Cached Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3
(Date:5/19/2013)... (PRWEB) May 19, 2013 Passages Malibu, ... treatment center, has announced this week the launch of ... the brands’ social media channels. “We are always ... treatment community and to get feedback regarding sobriety, what’s ... CEO and co-founder of the Passages Addiction Treatment ...
(Date:5/19/2013)... Argentina: Yoga classes ( clases de Yoga ) will ... Sivananda Yoga Vedanta Center. The center is located ... are 90 minutes and are offered all week long. ... environment, allowing visitors to enjoy the benefits of Yoga, ... , The Yoga classes follow the following principles: , ...
(Date:5/19/2013)... Ponte Vedra Beach, Florida (PRWEB) May 19, 2013 ... healthcare value and market access, is pleased to unveil ... online trade show environment that provides a powerful array ... solutions to partners in the US and abroad. , ... technology, and will offer attendees the look and feel ...
(Date:5/19/2013)... The legal team at Pulaski & ... concerted effort to connect women and families coping with ... Yaz, Yasmin & Ocella with the legal representation they ... the notorious birth control drugs as well as news ... Yaz, Yasmin & Ocella were very popular birth control ...
(Date:5/18/2013)... Cambridge House of Maryville , a BMA ... area, is hosting a Memorial Day Weekend Barbecue from 11 ... community, which is located at 6960 State Rte. 162 in ... on Medicaid, who need some help to maintain their independence. ... by homemade ice cream for dessert,” says Tracy Skaer-Henry, Administrator ...
Breaking Medicine News(10 mins):Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Metro East Affordable Assisted Living Community to Host Memorial Day Weekend Barbecue 2
... risk of breast cancer, most young women who were treated ... appropriate mammography screening, according to a study in the January ... chest radiation for a pediatric malignancy face a significantly increased ... of breast cancer begins to increase as early as 8 ...
... alternating cycles of chemotherapy and radiation have similar outcomes ... to data from a randomized controlled trial in the ... the National Cancer Institute. , Previous trials in ... followed by radiation was as effective as total removal ...
... Papillary Thyroid Cancer ,A germ-line mutation in the ... with multi-nodular goiter (MNG) and with progression to papillary thyroid ... have MNG progress to PTC, but a genetic link between ... to be involved in thyroid development and is expressed at ...
... HAMILTON, BERMUDA, Jan. 27 Warner Chilcott Limited (Nasdaq: ... year 2009 results.Total revenues for 2009 are expected to be ... results primarily being driven by LOESTRIN 24 FE, DORYX, and ... is anticipated to be in the range of 79% to ...
... to Protect World,s Supply of Donated Blood ... Continued Expansion into New Global Markets and ... PANTHER Instrument- Companies Also Plan Exploratory Collaboration ... Guidance Including Additional Revenue and Profit from ...
... Holmes (Amex: HH ) today announced the ... General Counsel and Corporate Secretary. He has also ... Rosenblum has over 23 years of corporate legal experience ... contract, consumer and other class actions, as well as ...
Cached Medicine News:Health News:Many women who survived childhood cancer do not undergo recommended breast cancer screening 2Health News:Sequential and alternating chemotherapy and radiation equally effective in larynx cancer therapy 2Health News:Also in the Jan. 27 JNCI 2Health News:Also in the Jan. 27 JNCI 3Health News:Also in the Jan. 27 JNCI 4Health News:Warner Chilcott Announces 2009 Financial Guidance 2Health News:Warner Chilcott Announces 2009 Financial Guidance 3Health News:Warner Chilcott Announces 2009 Financial Guidance 4Health News:Warner Chilcott Announces 2009 Financial Guidance 5Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 2Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 3Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 4Health News:Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration 5Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 2Health News:Hooper Holmes Names Mark Rosenblum Senior Vice President, General Counsel and Corporate Secretary 3
... reliable strength for temporary wound support. ... compliant and stretchable support material is ... is not required. Predictable absorption. Polyglactin ... inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... designed for the repair of abdominal hernias. ... has two distinct sides. One side ... layer of sodium hyaluronate and carboxymethylcellulose (similar ... coated side is bioresorbable, providing a temporary ...
... Human explant studies have confirmed Atriums ... maximum clinical performance in hernia repair. ... thinner and less dense hernia mesh ... rigid repair. Since 1994, when Atrium ...
Medicine Products: